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ABSTRACT
Alternative splicing can produce multiple protein
products with variable domain composition from a
single gene. The mouse Tcf7l2 gene is subject to
alternative splicing. It encodes TCF4, a member of
the T-cell factor (TCF) family of DNA-binding
proteins and a nuclear interaction partner of
b-catenin which performs essential functions in
Wnt growth factor signalling. Multiple TCF4
isoforms, potentially exhibiting cell-type-specific
distribution and differing in gene regulatory pro-
perties, could strongly influence tissue-specific
Wnt responses. Therefore, we have examined
mouse Tcf7l2 splice variants in neonatal tissues,
embryonic stem cells and neural progenitors. By
polymerase chain reaction amplification, cloning
and sequencing, we identify a large number of
alternatively spliced transcripts and report a highly
flexible combinatorial repertoire of alternative
exons. Many, but not all of the variants exhibit a
broad tissue distribution. Moreover, two functionally
equivalent versions of the C-clamp, thought to rep-
resent an auxiliary DNA-binding domain, were
identified. Depending upon promoter context and
precise domain composition, TCF4 isoforms
exhibit strikingly different transactivation potentials
at natural Wnt/b-catenin target promoters. However,
differences in C-clamp-mediated DNA binding can
only partially explain functional differences among
TCF4 variants. Still, the cell-type-specific comple-
ment of TCF4 isoforms is likely to be a major deter-
minant for the context-dependent transcriptional
output of Wnt/b-catenin signalling.
INTRODUCTION
T-cell factors (TCF) constitute a large family of evolution-
ary conserved HMG-box-containing DNA-binding
proteins and transcriptional regulators. Although the
founding members of the family, TCF1 and lymphoid
enhancer factor 1 (LEF1), were initially identiﬁed for
their role in Wnt-independent control of gene expression
in lymphocytes (1–3), at present, TCFs are most
intensively studied as nuclear eﬀectors of Wnt growth
factor signalling. In this context, TCFs serve as assembly
platforms for multifactorial transcription complexes,
which, depending upon their composition, act either to
repress Wnt target genes or to stimulate their expression
[reviewed in refs (4–6)]. Wnt/b-catenin pathway activation
induces compositional changes in these transcription
factor complexes (7) by promoting intracellular accumu-
lation and nuclear entry of b-catenin. This enables the
formation of b-catenin::TCF complexes (8–10) through
binding of b-catenin to a domain located at the
N-termini of TCFs. Concomitantly, Grg/TLE trans-
criptional corepressors are displaced from an adjacent
region in TCFs (11), and coactivators are recruited (4).
Thereby, Wnt/b-catenin target genes are switched from
inactive to active states.
The ability of Wnt signalling to elicit diﬀerent responses
at diﬀerent time points and in diﬀerent tissues critically
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sion in a highly context-dependent manner. The mecha-
nisms whereby this functional diversiﬁcation is achieved
are largely unknown. However, TCFs are likely to have a
central part in the process of target gene selection and,
thereby, in shaping cell-type-speciﬁc Wnt eﬀects. In
support of this, it has been shown that TCF3 and LEF1
have contrasting eﬀects on formation of the embryonic
body axis in Xenopus laevis (8,10,12–14). Furthermore,
genome-wide and locus-speciﬁc chromatin immunopre-
cipitation (ChIP) studies uncovered distinct patterns of
promoter occupancy by TCF family members in mouse
and human cell lines (15–17). Moreover, TCF family
members diﬀer in their ability to support b-catenin-
dependent transactivation at selected target gene pro-
moters (16,18,19). Thus, there is increasing evidence for
functional diversity and non-redundant activities among
TCF family members (12–14,18–23).
Functional diﬀerences among TCFs most likely arise
from variation in protein structure. In particular, regions
outside of the b-catenin interaction site and the HMG-box
DNA-binding domain show considerable amino acid
sequence divergence. The structural diversity of TCFs is
further increased due to dual promoter usage and exten-
sive alternative splicing (5). Thus, each of the TCF genes
can give rise to diﬀerent protein isoforms which has
clear functional implications. For example, the TCF1E
splice variant harbours a so-called C-clamp domain
C-terminally to the HMG-box. The C-clamp is a bipartite
amino acid motif featuring four characteristic cysteines
and two clusters of amino acids enriched in basic
residues (24). It forms an auxiliary DNA-binding
domain which enables TCF1E to recognize speciﬁc
subsets of TCF-binding elements (TBEs). In contrast to
TCF1E, the TCF1B splice form does not contain a
C-clamp (24). As a result, TCF1B does not bind to the
LEF1 promoter and, hence, is unable to transactivate it
(5,24). Aside from the C-clamp other parts of TCFs,
which are varied due to alternative splicing, have also
been shown to inﬂuence their gene regulatory capacity
(12,14). Thus, a growing body of information suggests
that alternative splicing can generate a multitude of TCF
protein isoforms with possibly unique capabilities to
support diﬀerential gene expression by Wnt signalling.
In the human and mouse genomes, the TCF4 genes
(oﬃcial names TCF7L2 and Tcf7l2) consist of 17 exons.
However, current information about variable exon com-
position of TCF4 transcripts is almost exclusively derived
from studies using human cell lines and tumour samples
(25–27). Three regions subject to alternative splicing were
identiﬁed. The conditional exon 4 encodes a 23 amino acid
protein domain without known function. Skipping of the
splice donor at the 30-end of exon 8 yields TCF4 tran-
scripts, which give rise to TCF4N isoforms (28,29). The
TCF4N isoforms consist of the N-terminal part of TCF4
including the b-catenin binding domain but lack the
HMG-box and all other elements beyond it. The
TCF4N variants likely function as dominant negative
factors in Wnt signalling by diverting b-catenin from
cognate target genes (28,29). In addition, variable use of
alternative splice donor and acceptor sites at exons 7 and 9
leads to protein isoforms in which amino acid sequences
derived from exon 8 are ﬂanked by diﬀerent combinations
of LVPQ and SxxSS amino acid motifs. The presence or
absence of these elements alters transcriptional properties
of Xenopus TCFs (12,14). However, their role in mamma-
lian TCFs is unknown. Finally, extensive alternative
splicing of exons 13, 14, 15 and 16 in various combinations
generates TCF4E (also known as TCF4L), TCF4M (also
known as TCF4B) and TCF4S isoforms with highly
diverging C-termini (25–27,30). Only TCF4E variants
harbour a complete C-clamp and, in addition, contain
two binding motifs for the transcriptional repressor
Carboxy-terminal Binding Protein (CtBP) (31). All other
TCF4 isoforms lack the CtBP-binding sites and possess
either no C-clamp (TCF4M) or only an incomplete
version of it (TCF4S) (25–27). To which extent the
presence of variable C-termini alters the functional
properties of TCF4 isoforms is not known.
Compared to their human counterparts, much less is
known about the range of alternative splicing of mouse
Tcf7l2 transcripts (30,32–34). Moreover, there is only very
limited information about the tissue-speciﬁc distribution
of Tcf7l2 splice variants, and about how altered domain
architecture aﬀects TCF4 protein function. Such knowl-
edge, however, might provide invaluable insights into the
tissue-speciﬁc activities of TCF4 as nuclear eﬀector of
Wnt/b-catenin signalling. Because of this, we have begun
a systematic compilation of alternative splice forms of
Tcf7l2 transcripts in diﬀerent mouse tissues and cell
types. Here we describe a multitude of Tcf7l2 splice
variants, which are highly similar in design to the
human gene transcripts, and which include hitherto
unknown versions of the C-clamp. Most of the variants
identiﬁed show a broad tissue distribution albeit relative
proportions to each other can vary. Based on the presence
or absence of C-terminal amino acid signature motifs,
TCF4 splice variants fall into one of three main classes.
Representatives of each of these were functionally tested
with respect to promoter-speciﬁc transactivation and
DNA binding. Our ﬁndings show that the extended
C-terminal domains of ‘E’-type variants endow TCF4E
isoforms with unique properties with respect to
promoter recognition and activation.
MATERIALS AND METHODS
Cell culture, transient transfections and luciferase
reporter gene assays
Human HEK293 and U2-OS cells (ATCC # CRL-1573,
ATCC # HTB-96) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (PAN-Biotech) containing 10% fetal calf
serum (Invitrogen), 10mM Hepes buﬀer (PAN-Biotech),
1% MEM non-essential amino acids (Invitrogen) and
100units/ml penicillin–streptomycin. The murine embry-
onic stem cell (ESC) line E14, murine C17.2 neural pro-
genitor cells (NPCs) and C2C12 myoblasts (ATCC #
CRL-1772) were cultured as previously described
(35,36). For western blotting analysis, 5 10
5 HEK293
cells (per well of a 6-well plate) were transfected with
2.5mg of expression vectors for TCF4 isoforms E2,
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reagent (Roche Applied Science). For ChIP, 1.4 10
7 cells
seeded in 15cm dishes were transfected with 1.5ml of a
calcium phosphate–DNA coprecipitate containing 10mg
each of the TCF4 expression vectors and the various
promoter constructs. For immunostaining, 2 10
4
U2-OS cells seeded per well of 24-well plates on gelatine-
coated cover slips were transfected 4h after plating using
the FuGENE6 reagent (Roche Applied Science) and
100ng of the TCF4E2, TCF4E2ex4, TCF4E4, TCF4M1
and TCF4S2 expression vectors, respectively. For
luciferase assays, 1 10
5 HEK293 cells seeded per well
of a 24-well plate were transfected with FuGENE6
reagent (Roche Applied Science) 4h after plating. Cells
received a mixture of 100ng of ﬁreﬂy luciferase reporter
plasmid with Wnt target gene promoters as indicated,
10ng of the Renilla luciferase expression vector
pRL-CMV (Promega), 100ng of plasmid DNA for
expression of a constitutively active form of b-catenin
(18) and increasing amounts (1, 5, 25 and 125ng) of
expression vectors for TCF4 splice variants. Total
amounts of transfected DNA were kept constant by
adding appropriate amounts of the empty expression
vector pCS2+. Where indicated, transfected cells
received 200ng/ml of recombinant Wnt3a (R&D
Systems) 16h prior to harvest. Reporter gene activities
were determined as described (18), and Renilla luciferase
activity was used for normalization. All results shown rep-
resent average values obtained from at least three indepen-
dent experiments including standard deviations.
RNA isolation, reverse transcription polymerase chain
reaction (RT–PCR) and cloning of RT–PCR products
RNA isolations from cell lines and tissue samples of
three-days-old mice, cDNA synthesis and subsequent
RT-PCRs were performed as described (16) using the
NucleoSpin RNA II kit (Macherey and Nagel) and
Superscript II reverse transcriptase (Invitrogen) following
the manufacturer’s protocols. For tissues, 30mg of
starting material was used. PCR products were separated
by electrophoresis on 6–10% polyacrylamide gels, or on
2% agarose gels. DNA fragments were isolated with the
DNA and Gel Band Puriﬁcation Kit (GE Healthcare).
Subsequent cloning of PCR products into pCR4-TOPO
vector was performed using the TOPO TA Cloning Kit
for Sequencing (Invitrogen). Sequence analyses were
carried out using the BigDye cycle sequencing Kit
(Applied Biosystems) with the help of the sequencing
core facility of the University Medical Center Freiburg,
Germany.
Plasmids and generation of TCF4 expression constructs
The expression plasmids pCS2+ and pCS2+b-catS33A,
as well as the luciferase reporters pGL3b-Axin2, pGL3b-
Cdx1, pCycD1-973XP2 and pS01234 were previously
described (18,37–42). To generate eukaryotic expression
vectors for TCF4 splice variants, the mouse TCF4M1
isoform in pFLAG-CMV-2 (32) was used as starting
point. To produce TCF4 isoforms E2 and S2 from this
vector, the entire plasmid including TCF4 sequences was
ampliﬁed with divergent primers located in exons 12 and
17 using Pfu Ultra II HS DNA Polymerase (Stratagene;
for primer sequences see Table 1). The linearized vector
was then ligated with 50 phosphorylated PCR products
containing exons 13–14 and 13–14–15, respectively,
which were derived from cloned RT-PCR fragments in
pCR4-TOPO. Exon 4 sequences were introduced into
TCF4E2 by a similar strategy. Primer pairs E4f/E4r and
E3bluntr/E5bluntf (Table 1) were used for ampliﬁcation
of exon 4 sequences and the recipient vector backbone.
TCF4E4 was derived from TCF4S2 by deleting exon 14
sequences. For this, plasmid sequences were PCR
ampliﬁed with divergent primers in exons 13 and 15
(E13bluntr/E15bluntf; Table 1) followed by phospho-
rylation and religation. All expression cassettes for the
TCF4 isoforms were sequence veriﬁed. For expression
in vitro, the cDNAs for the corresponding TCF4
isoforms were cut out from pFLAG-CMV-2 expression
vectors with EcoRI and ligated into the pZero-2 vector
(Invitrogen).
Preparation of nuclear extracts
For the preparation of nuclear extracts, cells from two to
three conﬂuent 15cm dishes were used. Cells were washed
once with ice-cold PBS, scraped from the dishes and trans-
ferred into 15ml centrifuge tubes. After centrifugation at
1200 g for 1min, the cell pellet was resuspended in 1ml
of hypotonic swelling buﬀer [10mM Hepes pH 7.9, 10mM
NaH2PO4, 1.5mM MgCl2, 0.5mM spermidine, 10mM
NaF, 0.1mM Na3VO4 and Complete
TM protease inhibitor
(Roche Applied Science)]. Upon incubation on ice for
20min, cells were disrupted by douncing in a glass-glass
homogenizer with 50 strokes of a tight-ﬁtting pestle.
Thereafter, nuclei were pelleted at 800 g for 5min. The
cytoplasmic supernatant was removed and the nuclei were
washed twice with 1ml hypotonic swelling buﬀer prior to
extraction with 250ml high salt buﬀer [30mM Hepes pH
7.9, 25% glycerol, 400mM NaCl, 0.3mM EDTA, 12mM
MgCl2 and Complete
TM protease inhibitor (Roche
Applied Science)] on ice for 45min. The nuclear extract
was cleared by centrifugation at 100000 g and 4 C for
30min and stored at  80 C until use.
Western blotting and indirect immunoﬂuorescence
For western blotting analysis cells were lysed in IPN150
buﬀer [50mM Tris/HCl pH 7.6, 150mM NaCl, 5mM
MgCl2, 0.1% NP40, Complete
TM protease inhibitor
(Roche Applied Science), 1mM DTT, 0.1mM Na3VO4,
1mM PMSF, 10mM NaF] for 30min on ice. Cell lysates
were cleared by centrifugation at 20000 g and 4 C for
10min. Protein concentrations in cell lysates were deter-
mined using the DC protein assay kit (BioRad). Following
SDS–PAGE, proteins were transferred onto nitrocellulose
membranes using a semi dry blotting apparatus. As
blocking reagent, 2% skim milk powder in TBS-T buﬀer
was used. For detection of TCF4 isoforms, a mouse
monoclonal antibody (6H5-3, Upstate) was used at a
1:1000 dilution in TBS-T buﬀer containing 0.025% BSA
and 0.02% sodium azide. LEF1 and GSK3b were detected
in nuclear extracts using mouse monoclonal antibodies
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610201, BD Transduction Laboratories, 1:1000). For the
detection of TCF1 a rabbit monoclonal antibody (clone
C63D9, cell signaling: 1:2000) was utilized. A goat
polyclonal antiserum was employed for the detection of
TCF3 (M-20, Santa Cruz Biotechnology: 1:1000).
Visualization of antibody::antigen complexes was
done with appropriate species-speciﬁc horse radish
peroxidase-coupled antibodies diluted 1:10000 and a
chemiluminescent substrate solution consisting of 0.1M
Tris/HCl, pH 8.6, 250mg/ml luminol, 110mg/ml
p-hydroxycoumaric acid and 0.0105% H2O2. Substrate
incubation time was 2min prior to exposure.
Alternatively, the LumiGLO substrate (Kirkegaard and
Perry Laboratories) was used according to recommenda-
tions of the manufacturer. For immunolocalizations of the
diﬀerent TCF4 isoforms, U2-OS cells were immuno-
stained 48h after transfection as previously described
(43). Mouse monoclonal TCF4 antibody 6H5-3 was
used at a 1:250 dilution. The secondary antibody was an
Alexa-555 conjugated goat anti-mouse IgG (molecular
probes) at a 1:1000 dilution.
Transcription and translation in vitro and electrophoretic
mobility shift assays
TCF4 splice variants were transcribed and translated in
vitro using the TNT SP6 high-yield wheat germ protein
expression system (Promega) with 6mg of plasmid DNA
in 50ml reactions. Equal expression levels of the diﬀerent
isoforms were controlled by western blotting. Binding
reactions for electrophoretic mobility shift assays
(EMSAs) were composed as described (18), except that
the total volume was 20ml and 50-biotinylated DNA
probes were used at concentrations of 1.0fmol/ml( Cdx1
probes) and 0.5fmol/ml( Siamois probe), respectively.
DNA probes consisted of complementary pairs of syn-
thetic oligonucleotides covering Cdx1 promoter
sequences, or were generated by PCR with biotinylated
primers using Siamois promoter plasmid DNA as
template. Sequences of the Cdx1 probes and the Siamois
primers are listed in Table 2. For supershifts, binding reac-
tions were supplemented with 2.0mg of an anti-TCF4
antibody (N-20, Santa Cruz Biotechnology) and anti-
body::antigen complex formation was allowed for 10min
prior to adding the biotin-labelled probe. Binding reac-
tions were resolved by electrophoresis on polyacrylamide
gels in 0.5 TBE running buﬀer and transferred onto
hybond N
+ nylon membrane (GE Health Care) for 1h
at 340mA in the same buﬀer. DNA was crosslinked
Table 2. Sequences of 50-biotinylated oligonucleotides used to generate EMSA probes
Sequence
a
TBE4 50-CGAGGCTTCCCCCCGCTTTGAAATGCAAAGCCGCCC-30
TBE4 mTBE 50-CGAGGCTTCCCCCCGCTTTGgcATGCAAAGCCGCCC-30
TBE4 mCCG 50CGAGGCTTCCCCCCGCTTTGAAATGCAAAGCtGCCC-30
TBE3/4 50-GGGCTTCCCCCTTTGATTCGCGGCCCCGAGGCT-TCCCCCCGCTTTGAAATGCAAAGCCGCCC-30
TBE3/4 mTBE 50-GGGCTTCCCCCTTTGgcTCGCGGCCCCGAGGCT-TCCCCCCGCTTTGgcATGCAAAGCCGCCC-30
TBE3/4 mCCG 50-GGGCTTCCCCCTTTGATTCGCGGCCCtGAGGCT-TCCCCCCGCTTTGAAATGCAAAGCtGCCC-30
TBE30/3/4 50-ATTTGTCTCCTTTTGAACCCCCTCGCCCGACGGGCTTCCCCCTTTGAT-TCGCGGCCCCGAGGCTTCCCCCC
GCTTTGAAATGCAAAGCCGCCC-30
TBE30/3/4 mTBE 50-ATTTGTCTCCTTTTGgcCCCCCTCGCCCGACGGGCTTCCCCCTTTGgc-TCGCGGCCCCGAGGCTTCCCCCCGC
TTTGgcATGCAAAGCCGCCC-30
TBE30/3/4 mCCG 50-ATTTGTCTCCTTTTGAACCCCCTCGCCtGACGGGCTTCCCCCTTTGAT-TCGCGGCCCtGAGGCTTCCCCCCGC
TTTGAAATGCAAAGCtGCCC-30
SiaP( 233) sense 50-TGTCATCAGAATCATCAAAGGACC-30
SiaP(+5) antisense 50-CCAAAATGTTGGTCCACTCTGTCC-30
aUnderlined nucleotides mark the TBE and 50-RCCG-30 motifs; lower case denotes mutated nucleotides.
Table 1. Primer sequences
Sequence
Primer for RT–PCR
E1f 50-AAACAGCTCCTCCGATTCC-30
E4f 50-CAATCCGGCAGCACTCATTAC-30
E5r 50-TCTGCTCTGGAGGCTTCCTG-30
E7f 50-TCCGCACCCTCCAGATATC-30
E9r 50-GAGTGAGCCGACGTCACTC-30
E12f 50-ACAAGCAGCCGGGGGAAAC-30
E16r 50-CATCATAATATTCCAAATTC-30
E17r1 50-AGCCTAGCAGATGCGGTGAG-30
E17r2 50-GTCTGTGACTTGGCGTCTTG-30
N3’r 50-ATATCATATGTCTAGAGGGCCT
CACAAGAAG-30
Primer for cloning
E3bluntr 50-GGTTCGGGCGGTGGGCGAGAG-30
E5bluntf 50-TATCTCCAGATGAAATGGCCAC-30
E4bluntf 50-CTCCATTTTCAATCCGGCAG-30
E4bluntr 50-CTGAATTGCAATCTGGTGTTC-30
E17bluntf 50-GAGAAAAAAAAAGTGCGTTCG-30
E12bluntr 50-CGTTGGTTTCCCCCGGCTG-30
E13f 50-AACACAGCGAATGTTTCC-30
E13bluntr 50-CTGTGATCGGAGGAAGCG-30
E14bluntr 50-CTGCAGGGGCCGCACCAG-30
E15bluntf 50-ATGCAAATACGCCAAAGAAG-30
E15r 50-CTGCAGGGTTTGCACCATAAAG-30
Primer for ChIP
Cdx1 440 50-CGTTTGAAGTCAGCCTTGCT-30
Cdx1 307rev 50-CCTGGGTTACAGGTGGAGAA-30
SiaP for 50-GGTTCTGCTGCCAAGTTAGG-30
SiaP rev 50-ATGCACCCTGAAAGAATTGG-30
pGL3basic+7820 50-CGCTTTCTTCCCTTCCTTTC-30
pGL3basic+8005rev 50-AAGGGCGAAAAACCGTCTAT-30
GAPDH 50-ACCACAGTCCATGCCATCACT-30
GAPDH rev 50-GTCCACCACCCTGTTGCTGTA-30
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‘Chemiluminescent Nucleic Acid Detection Module’
(Pierce). Images were recorded with the LumiImager and
X-ray ﬁlms.
ChIP
Solubilized, fragmented chromatin from transfected
HEK293 cells was prepared following exactly the instruc-
tions of the ChIP-IT
TM kit with the enzymatic chromatin
shearing module (Active Motif). Digestion of chromatin
was carried out for 30min at 37 C with occasional mixing.
For immunoprecipitation, 200mg sheared chromatin and
2mg of a goat polyclonal anti-TCF4 antibody (N-20;
Santa Cruz Biotechnology) or 2mg of goat IgG control
antibodies, respectively, were combined, and samples
were further processed as described (16). To monitor
protein recovery of the TCF4 splice variants in immuno-
precipitates, one twentieth of each sample was analysed
alongside with one twentieth of the input chromatin
by SDS–PAGE and western blotting using a mouse
monoclonal anti-TCF4 antibody (6H5-3; Upstate).
Images were recorded using the LumiImager and the
LumiAnalyst software (Roche Applied Science) and
relative quantities of the TCF4 isoforms were determined.
This information was used to normalize the amounts of
DNA which had been co-precipitated with each of the
TCF4 isoforms, and which were used as templates in
real-time PCR analyses. Primer pairs used to amplify the
investigated promoters, a portion of the pGL3 basic
control vector, and GAPDH as non-speciﬁc control,
respectively, are listed in Table 1. Levels of promoter
DNA and GAPDH control sequences which were
precipitated by speciﬁc and non-speciﬁc antibodies, were
calculated as fractions of the input DNA. GAPDH values
were used for normalization. Results shown are average
values and the corresponding standard deviations from at
least three independent experiments.
RESULTS
Identiﬁcation of Tcf7l2 splice variants in mouse tissues
and cell lines
To examine the occurrence and tissue-speciﬁc distribution
of splice variants derived from the mouse Tcf7l2 gene we
reverse transcribed RNA from mouse neonatal tissues,
ESCs, and NPCs. Sequence variability was examined
between exons 1–9 and 12–17, where alternative splicing
and variable use of splice signals has been extensively doc-
umented for the human and Xenopus genes (Figure 1A)
(14,25–27). Tcf7l2-speciﬁc sequences were PCR-ampliﬁed
with various combinations of exon-speciﬁc primer pairs
(Figure 1A, Table 1). First, we analysed Tcf7l2 transcripts
with or without exon 4. PCR products with the corre-
sponding size diﬀerences were detected in all tissues
analysed, as well as in ESCs and NPCs (Figure 1B, top
panel, Supplementary Figure S1). Their identity was con-
ﬁrmed by subcloning and sequencing of PCR products
from ESCs, NPCs, gut and brain samples. Interestingly,
the relative proportions of transcripts containing or
lacking exon 4 varied. Exon 4-containing transcripts are
comparably less abundant in heart, brain and ESCs
(Figure 1B). Furthermore, nested PCR ampliﬁcation
with primers located in exons 4, 12 and 17 yielded
complex mixtures of products suggesting that exon 4
occurs in various combinations with the alternatively
spliced exons 13–16 (Supplementary Figure S2). Thus,
incorporation of exon 4 does not appear to be restricted
to a particular subset of splice forms.
Next, we investigated sequence variations around exon
8. These can arise from the use of alternative splice donor
and acceptor sites, or from retention of intronic sequences
downstream of exon 8 (Figure 1A). In the ﬁrst case, exon 8
can be ﬂanked by additional sequences giving rise to the
LVPQ and SFLSS amino acid motifs (14,25,44).
Corresponding variants containing either both motifs or
just the LVPQ motif were also identiﬁed for mouse Tcf7l2
(Supplementary Figure S1). Transcripts which lack both
elements simultaneously or which incorporate just the
SFLSS motif were not found. However, their existence,
perhaps at a very low abundance, cannot be ruled out.
Tcf7l2 transcripts in which the splice donor at the 30-end
of exon 8 is suppressed give rise to TCF4N proteins (28).
Such transcripts were found in all tissue samples at similar
levels. However, they were hardly detectable in ESCs
(Figure 1B).
Finally, we turned to transcripts generated by alterna-
tive splicing of exons 12–17. PCR with primer pairs
located in exons 12 and 17 yielded a complex pattern of
PCR products (Figure 1B). To unequivocally determine
their precise exon combinations, the PCR products
obtained from brain and gut samples, as well as from
ESCs and NPCs were excised from gels, subcloned and
sequenced. Thereby, we identiﬁed splice variants E1–E4,
M1–M3, and S1–S4, S6 and S8, and assigned them to
speciﬁc PCR products (Figure 1B and C).
Within the limitations of the experimental approach, it
appears that most of the Tcf7l2 exon 12–17 splice variants
are expressed in every tissue or cell type investigated. As in
case of exon 4, however, their relative amounts vary. The
most prominent example for this is provided by transcripts
S3 and S6 which appear particularly abundant in brain
tissue (Figure 1B). S3 and S6 transcripts contain exon
16, which is absent from the majority of the other
isoforms. This raised the possibility that exon 16 was
incorporated in a brain-speciﬁc manner. Therefore, we
more speciﬁcally examined the existence and tissue-speciﬁc
distribution of exon 16-containing transcripts by PCR
ampliﬁcation with the primer combination E12f/E16r.
Three PCR products with a length of 246, 173 and
122bp, respectively, were detected. The 122bp fragment,
which based on its size is presumably derived from splice
variants S4 or S6, was detected in cDNA from brain and
to a lesser extent from gut. The 246bp fragment, which
corresponds in size to the splice variant S8, was observed
at low levels only in RNA from gut. However, originally
we identiﬁed the S8 isoform upon cloning and sequencing
of a cDNA fragment derived from brain RNA. Therefore,
TCF4S8 does not appear to be strictly gut-speciﬁc. In
contrast to the tissue-restricted occurrence of the 122
and 246bp bands, the 173bp fragment could be ampliﬁed
from RNA of all tissues analysed. Its size matches most
1968 Nucleic Acids Research, 2010, Vol.38, No. 6closely to that of the S3 isoform. Alternatively, it might be
derived from a variant with the C-terminal exon combi-
nation 12–13–15–16. Because the latter isoform was not
detected by subcloning of PCR fragments and subsequent
sequencing, we assume that the PCR fragment detected
most likely is derived from TCF4S3. Irrespective of this,
closer inspection of Tcf7l2 transcripts containing exon 16
reveals that some of these isoforms show a rather narrow
range of tissue-speciﬁc expression, while others are widely
distributed. Furthermore, while transcripts with exon 16
are indeed expressed at highest levels in brain, they are not
exclusively present in this tissue.
Depending upon the preceding exon combination,
diﬀerent open reading frames are used for translation of
Figure 1. Comparison of expression patterns of TCF4 splice variants in mouse tissues and ES cells. (A) Simpliﬁed structural schemes for TCF4
proteins (top) and the mouse Tcf7l2 gene (bottom). The Tcf7l2 gene consists of 17 exons, some of which are subject to alternative splicing (exons 4,
13–16; labelled in red). Constitutive exons are labelled in green. Additional variation of Tcf7l2 mRNA sequences is generated due to the use of
alternative splice acceptor and donor sites, respectively, in exons 7, 8 and 9. Aﬀected regions are also indicated by red boxes. The position of the start
codon in exon 1 is marked. Which of the potential stop codons following exon 8 or within exons 15, 16 and 17 is used, depends on the particular
exon combination present in the ﬁnal mRNA. Retention of sequences following exon 8 (labelled N) in the ﬁnal mRNA generates the TCF4N variant.
Exon lengths are drawn approximately to scale. Horizontal arrowheads indicate the positions and the orientation of primers used in RT-PCR
reactions. Some of the structural features of TCF4 proteins are indicated and linked with connectors to the exons by which they are encoded. Dashed
lines skirt the highly variable C-terminal parts of TCF4 derived from exons 13–17. b-cat: b-catenin binding domain; Grg: binding motif for
groucho-related gene (Grg) products (73); HMG: HMG box; NLS: nuclear localization signal. (B) Expression analyses of TCF4 splice variants
in diﬀerent mouse tissues and ES cells. Upon isolation of RNA from mouse ES cells and tissue samples from 3-days-old mice, cDNA was
synthesized, and TCF4 splice variants were ampliﬁed by PCR using exon-speciﬁc primer combinations as indicated. Ampliﬁcation of GAPDH
sequences served to control RNA and cDNA integrity. PCR products were separated by gel electrophoresis, and visualized by ethidium bromide
staining. To determine the exon combination represented by the various DNA fragments, PCR products were subcloned and sequenced. The deduced
size of the PCR products and their assignment to TCF4 E, S and M groups of splice variants is indicated on the right side of the panels. PCR
products from brain tissue labelled by asterisks represent isoforms S3 and S6. (C) Summary of the C-terminal TCF4 splice variants identiﬁed. Red
exons are alternatively spliced whereas green exons are constitutively used. Blue areas indicate untranslated regions. Positions of stop codons used are
shown. Splice variants were grouped depending upon whether the resulting translation products contain no C-clamp or complete and incomplete
versions thereof, respectively (Figure 2). Accordingly, the isoform formerly denoted S5 (26) was reclassiﬁed as M3.
Nucleic Acids Research,2010, Vol.38, No. 6 1969exons 15, 16 and 17. This distinction can be used to
classify Tcf7l2 transcripts into three groups giving rise to
TCF4E, TCF4M and TCF4S protein isoforms (Figures 1
and 2). The hallmark of the E isoforms (also known as L)
(25–27,44) is the presence of a complete C-clamp.
Interestingly, our analyses revealed that there are two
variants of the C-clamp in TCF4. TCF4E1 and TCF4E2
harbour a CRARF motif together with the conserved
cysteines, whereas TCF4E3 and TCF4E4 display
a CRALF motif in conjunction with the cysteines
(Figure 2). TCF4S variants contain only three of the
four conserved cysteines. Again, these can be combined
either with the CRARF or the CRALF motif. TCF4M
variants (also denoted B) (25–27,44) lack both the
cysteines and the CRARF/CRALF element.
To determine whether multiple variants of TCF4 exist
at the protein level, we performed western blotting exper-
iments with protein extracts from ESCs, NPCs and C2C12
myoblasts. Both, by use of a mouse monoclonal antibody
and with a goat polyclonal antiserum against TCF4, two
prominent protein bands were detected (Supplementary
Figure S3, Figure 5C). The slower migrating band of
 70kDa corresponds in size to the expected molecular
weights of TCF4E isoforms whereas the faster migrating
band of  50kDa matches the molecular weight of
TCF4M/S variants. The same two protein bands were
also revealed in reciprocal immunoprecipitation/immuno-
detection experiments with the two diﬀerent
anti-TCF4 antibodies (Supplementary Figure S3) further
corroborating that they represent TCF4 protein forms.
Some of the variants within the TCF4E and TCF4M/S
groups, respectively, are nearly identical in molecular
weight. Thus, it is possible that the 70 and 50kDa bands
each contain a collection of various TCF4E and TCF4M/
S species. Other variants, however, should be resolvable
by SDS–PAGE. The detection of only two dominant
TCF4 bands therefore suggests that some isoforms are
translated not at all or at much lower levels than others.
Regardless of this, our results show that at least one rep-
resentative of the TCF4E and TCF4M/S variants each is
expressed in tissue culture cells.
In summary, the analyses performed so far reveal that
the mouse Tcf7l2 gene exhibits the same extensive range of
alternative splicing and splice site usage as the human
gene. Although there is some tissue-speciﬁc variability in
their relative abundance, most transcript isoforms appear
to be present in a wide range of tissues. The near absent
levels of TCF4N encoding transcripts in embryonic stem
cells and the tissue-speciﬁc expression of some exon
16-containing isoforms may be notable exceptions. Thus,
the Tcf7l2 gene has the potential to give rise to a large
variety of TCF4 protein species including several forms
containing variants of the C-clamp.
Wnt/b-catenin target gene activation by
diﬀerent TCF4 isoforms
The structural divergence and diﬀerent domain composi-
tions strongly suggest that TCF4 isoforms also diﬀer in
function. However, an extended functional comparison of
TCF4 splice variants particularly in the context of natural
Wnt/b-catenin target gene promoters has not yet been
undertaken. Therefore, we generated expression con-
structs for mouse TCF4E2, TCF4M1 and TCF4S2, rep-
resentative for the three main groups of splice variants. In
addition, to obtain information about the functional
properties of amino acid sequences encoded by exon 4
and the CRALF variant of the C-clamp, expression
vectors for TCF4E2ex4 and TCF4E4 were made (Figure
3A). TCF4N was not included in these studies because its
functional properties have been extensively characterized
before (29). Western blotting was used to demonstrate
that all TCF4 variants were expressed at similar levels
after transfection of HEK293 cells (Figure 3B).
Furthermore, all TCF4 protein variants were located in
the nuclei of transfected U2-OS cells consistent with the
fact that each of them has an intact HMG box and a
nuclear localization signal (Figure 3C).
To compare TCF4 variants with respect to their
transactivation capacities we performed reporter gene
assays. HEK293 cells were cotransfected with luciferase
reporters, a construct encoding a b-catenin mutant with
alanine substitutions at its GSK3 and CK1 phospho-
acceptor sites to mimic an active Wnt/b-catenin
pathway, and expression vectors for the diﬀerent TCF4
variants. Promoter regions of the reporter constructs
were derived from the well-characterized Wnt/b-catenin
target genes Axin2, Cdx1, Cyclin D1 and Siamois. The
Axin2 gene is considered to be a ubiquitous Wnt/
b-catenin target without tissue-speciﬁcity (45). The
Cyclin D1 promoter, too, exhibits no cell-type speciﬁcity
and has been reported to be activated by Wnt/b-catenin
signalling in diﬀerent contexts (46–48). In contrast, the
Siamois and Cdx1 promoters are derived from highly
tissue- and stage-speciﬁc Wnt target genes (39,40,49).
Expression of constitutively active b-catenin was suﬃ-
cient to increase luciferase expression from the Axin2,
Cyclin D1 and Siamois promoters by 5–10-fold presum-
ably by making use of endogenous TCF family members
in HEK293 cells (Figure 4A–C). In contrast, the Cdx1
promoter did not respond to the b-catenin mutant alone
(Figure 4D). Co-expression of b-catenin and the TCF4
splice variants E2 and E4 strongly increased activity of
the Axin2, Siamois and Cdx1 promoters in a
dosage-dependent manner, irrespective of their C-clamp
version (Figure 4A, C and D). Presence of amino acid
sequences encoded by exon 4 dampened the trans-
activation capacity of TCF4E2. The TCF4M1 and
TCF4S2 variants diﬀered from the TCF4E isoforms in
several aspects. They could not cooperate with b-catenin
at the Axin2 and Cdx1 promoters and stimulated reporter
activity beyond levels obtained by b-catenin expression
alone only with the Siamois construct (Figure 4).
Importantly, the functional diﬀerences among the TCF4
splice variants are not related to diﬀerences in their inter-
actions with b-catenin. In coimmunoprecipitation experi-
ments, all TCF4 isoforms interacted with b-catenin with
similar eﬃciencies (Supplementary Figure S4). TCF4M1
and TCF4S2 are also unique in that they signiﬁcantly
elevated Cdx1 promoter activity in the absence of exoge-
nous b-catenin (Figure 4D). Finally, none of the TCF4
variants was able to synergize with b-catenin at the
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Nucleic Acids Research,2010, Vol.38, No. 6 1971Cyclin D1 promoter, nor did they inﬂuence its basal
activity. However, the b-catenin-induced Cyclin D1 acti-
vation does involve a TCF factor as it could be blocked by
dominant negative LEF1 and TCF4E2 lacking their
b-catenin-binding domains (Supplementary Figure S5).
Additionally, this also implies that TCF4E2 is able to
bind to the Cyclin D1 promoter, albeit non-productively.
Taken together, these analyses showed that TCF4 splice
variants diﬀer considerably in their gene regulatory
properties depending upon their precise domain composi-
tion. Furthermore, promoter context appears to be impor-
tant in determining whether TCF4 isoforms can eﬀectuate
their transactivation potential.
The Cdx1 reporter construct was the only one whose
activity could not be increased by constitutively active
b-catenin and an endogenous TCF family member in
Figure 3. Structure and expression of TCF4 protein isoforms chosen for functional analyses. (A) Schematic representation of TCF4 protein isoforms
E2, E2ex4, E4, S2, and M1. The location of binding domains for b-catenin (b-cat), Grg and CtBP corepressors, the HMG box, and the nuclear
localization signal (NLS) are indicated. The presence of a complete or incomplete (C) C-clamp is denoted. The TCF4E2, TCF4E2ex4 and TCF4S2
variants contain a CRARF motif as shown whereas in TCF4E4 a CRALF motif is present. The variant TCF4E2ex4 incorporates additional amino
acid sequences derived from exon 4 (orange box). TCF4M1 does not share amino acid sequences with TCF4E and TCF4S variants C-terminally to
the NLS as shown by the grey box. (B) Expression analyses of TCF4 isoforms. HEK293 cells were transfected with expression vectors for TCF4E2,
TCF4E2ex4, TCF4E4, TCF4M1 and TCF4S2. Control samples received the empty expression vector (lane 1). TCF4 proteins were detected in total
cell lysates 40h after transfection by western blotting. The same blot was subsequently probed with antibodies against a-Tubulin (a-Tub) as loading
control. Asterisks label residual TCF4S2 and TCF4M1 signals from the previous detection round. (C) U2-OS cells were transfected with expression
vectors for TCF4E2, TCF4E2ex4, TCF4E4, TCF4S2 and TCF4M1, respectively. Control samples received the empty expression vector. TCF4
isoforms were detected by indirect immunoﬂuorescence using a monoclonal antibody to TCF4 and an Alexa-555-labelled secondary antibody. Nuclei
were counterstained with DAPI. Phase contrast images (left) and an overlay (right) of Alexa-555 (aTCF4) and DAPI stainings are shown. Bars:
20mm.
1972 Nucleic Acids Research, 2010, Vol.38, No. 6Figure 4. TCF4 splice variants diﬀerentially activate Wnt/b-catenin target gene promoters. HEK293 cells were cotransfected with combinations of
ﬁreﬂy and Renilla luciferase reporter genes, control vector, expression vector for a constitutively active form of b-catenin, and increasing amounts of
expression vectors for TCF4 splice variants as indicated. Fireﬂy luciferase expression was driven by promoters from the Wnt/b-catenin target genes
Axin2 (A), Cyclin D1 (B), Siamois (C) and Cdx1 (D). Reporter gene activities were determined 40h post transfection. Bars represent relative luciferase
activities (RLA) compared to controls transfected with luciferase reporter plasmids and empty expression vectors only. Average values and standard
deviations from at least three independent experiments are given.
Nucleic Acids Research,2010, Vol.38, No. 6 1973HEK293 cells although it did respond to exogenous
TCF4E variants. Transcription of the endogenous Cdx1
gene can be stimulated by Wnt3a in mouse ESCs. To gain
further insight into the TCF requirements of the Cdx1
promoter, we performed additional transfection experi-
ments in HEK293 and ESCs. Unlike in HEK293 cells,
both treatment of transfected cells with recombinant
Wnt3a and expression of b-catenin robustly stimulated
the reporter in ESCs (compare Figures 5A and B). To
correlate this Cdx1 response with TCF expression and
activity, we examined the expression of LEF1, TCF1,
TCF3 and TCF4 in HEK293 and ESCs by western
blotting and asked which of the TCF family members
could synergize with b-catenin in Cdx1 reporter activa-
tion. Only TCF4E2 and TCF1E enhanced b-catenin-
dependent Cdx1 promoter activity (Figure 5A and B).
Interestingly, compared to HEK293 cells, ESCs possess
a greater abundance of TCF1 protein variants which,
based on their molecular weights, likely represent
‘E’-type isoforms (Figure 5C). Overall, these results
suggest that the failure of b-catenin and Wnt3a to
activate the Cdx1 promoter in HEK293 cells is due to
insuﬃcient levels of endogenous transactivation-
competent TCF4 and TCF1 isoforms. On the other
hand, they conﬁrm the particular transactivation
capacities of TCF proteins containing an extended ‘E’-tail.
DNA-binding properties of TCF4 protein isoforms at
diﬀerent Wnt/b-catenin target genes
The C-clamp is thought to facilitate transactivation by
TCFs through mediating extra DNA contacts with a
50-RCCG-30 motif situated adjacent to canonical TBEs
(24,50). The observed functional diﬀerences between the
TCF4 isoforms thus could be related to diﬀerences in
promoter recognition according to the presence or
absence of the C-clamp at their C-termini. To test this
possibility, we ﬁrst analysed the DNA-binding capacities
of the diﬀerent TCF4 isoforms in vitro by EMSAs.
TCF4E2, TCF4M1, and TCF4S2 were expressed in vitro
using a wheat germ based transcription and translation
system. Immunoblotting with a mouse monoclonal
antibody which recognizes all three TCF4 variants was
used to verify their expression at similar levels
(Supplementary Figure S6). EMSA probes used were a
Siamois promoter fragment with four potential TBEs,
and synthetic oligonucleotides covering mouse Cdx1
promoter sequences which contained the core
TCF-binding motif TBE4, a combination of TBEs 3 and
4, or the three TBEs 30, 3 and 4 together (18). Whereas
there are no 50-RCCG-30 motifs discernable next to the
core TBEs at the Siamois promoter, all three Cdx1 core
TBEs are ﬂanked by these elements (Figure 6A, Table 2).
Figure 5. Diﬀerential activation of the Cdx1 promoter in HEK293 cells (A) and mouse embryonic stem (ES) cells (B) by recombinant Wnt3a. Cells
were cotransfected with combinations of ﬁreﬂy and Renilla luciferase reporter genes, control vector, expression vector for a constitutively active form
of b-catenin, and constructs coding for TCF4E2, TCF1B, TCF1E, LEF1 and TCF3 as indicated. A cDNA construct for the human TCF4E2 variant
was used because it is present in the same vector backbone as the other TCF family members. Fireﬂy luciferase expression was driven by the Cdx1
promoter. To induce reporter gene expression by endogenous pathway components transfected cells received 200ng/ml recombinant Wnt3a (rWnt3a)
16h prior to harvest. Control cells remained untreated. Reporter gene activities were determined 40h post transfection. Bars represent relative
luciferase activities (RLA) compared to controls transfected with luciferase reporter plasmids and empty expression vectors only. Average values and
standard deviations from at least three independent experiments are given. hu: human; m: mouse. (C) Expression of endogenous LEF/TCF proteins
in diﬀerent cell lines. Nuclear extracts from HEK293 cells, ES cells, C17.2 neural progenitors (NPC) and C2C12 myoblasts were used for western
blotting and immunodetection of TCF4, TCF1, LEF1 and TCF3. Antibodies against GSK3b were used to monitor equal loading. As a control for
antibody speciﬁcity, epitope-tagged TCF1E, LEF1, TCF3 and TCF4E were used (controls). For this, HEK293 cells were transfected with expression
vectors for HA-tagged LEF/TCF proteins, whole cell lysates were prepared 40h after transfection, and aliquots containing roughly equal amounts of
the reference proteins were analysed in parallel with the nuclear extracts. The presence of the HA-tag accounts for size diﬀerences between controls
and cellular TCFs. Mw: molecular-weight standard; n.a.: not analysed.
1974 Nucleic Acids Research, 2010, Vol.38, No. 6At the Siamois promoter, two diﬀerent amounts of
the TCF4 proteins and antibody supershifts were used
to distinguish TCF4 isoform-dependent DNA binding
from endogenous activity in the wheat germ lysate
(Figure 6E). Indeed, dose-dependence of the signals and
the appearance of additional retarded bands upon appli-
cation of an anti-TCF4 antibody identiﬁed speciﬁc
TCF4::DNA complexes. Importantly, no major diﬀer-
ences in the respective binding capacities of TCF4E2,
TCF4M1 and TCF4S2 were evident. Similarly, all three
Figure 6. TCF4 isoforms diﬀerentially bind to Wnt/b-catenin target gene promoters. (A) DNA probes used for EMSAs. Top: The extended con-
sensus TBE sequence derived from CASTing experiments and the 50-RCCG-30 motif recognized by the TCF1 C-clamp (24). Nucleotide sequences
representing the heptameric TBE core (74,75) and the 50-RCCG-30 element are underlined. Promoter fragments from the Cdx1 and Siamois genes are
shown schematically. TBEs and their relative positions are indicated. Coordinates of the DNA fragments are given relative to the transcription start
site (+1; marked by an arrow at the Siamois promoter). Grey boxes indicate 50-RCCG-30 elements in the vicinity of the Cdx1 TBEs. Capital letters:
matches between core consensus and the actual TBEs, lower case: mismatches. Asterisks indicate the positions which were mutated in core TBE or
50-RCCG-30 motifs. (B–E) In vitro transcribed and translated TCF4 isoforms E2, M1 and S2, or a mock programmed wheat germ extract (C) were
used in EMSAs as indicated. A PCR fragment with Siamois promoter sequences (SiaP), or synthetic oligonucleotides harbouring Cdx1 promoter
sequences with single, double or triple combinations of TBEs 30, 3 and 4, were used as probes as schematically indicated on top of each panel. The
Cdx1 probes contained all wild-type sequences (WT) or base pair exchanges in every TBE (mTBE) or 50-RCCG-30 motif (mCCG) present as
indicated. At the Siamois promoter, two diﬀerent protein amounts were used (black boxes). For supershifts in panel E, a goat polyclonal TCF4
antibody (N-20) was added to the binding reactions (aTCF4). Speciﬁc protein::DNA complexes and positions of the unbound DNA probes are
marked. Asterisks indicate non-speciﬁc bands.
Nucleic Acids Research,2010, Vol.38, No. 6 1975TCF4 protein variants showed robust interactions with
the Cdx1 probes regardless of the presence or absence of
a C-clamp (Figure 6B–D, lanes 3–5). To determine to
which extent core TBEs and 50-RCCG-30 motifs contri-
buted to these interactions, additional EMSAs with
mono-, di- or trimeric Cdx1 probes were performed in
which either all core TBEs or all 50-RCCG-30 motifs,
respectively, had been mutated simultaneously. As
expected, the core TBE mutations completely abolished
DNA binding by TCF4E2, TCF4M1 and TCF4S2
(Figure 6B–D, lanes 7–9). DNA binding by TCF4M1
and TCF4S2 variants lacking a C-clamp was
not aﬀected by mutation of the 50-RCCG-30 motifs
(Figure 6B–D, lanes 12 and 13). In contrast, the ability
of TCF4E2 to interact with the monomeric TBE4 probe
was severely reduced in the absence of the 50-RCCG-30
motif (Figure 6B, compare lanes 3 and 11). However, at
the di- and trimeric probes the requirements of the
50-RCCG-30 motifs for eﬃcient TCF4E2::DNA comple-
xation was considerably less pronounced (Figure 6C and
D, compare lanes 3 and 11). Apparently, the presence of
multiple core TBEs within the physiologically more
relevant multimeric DNA probes can at least partially
compensate for mutation of the 50-RCCG-30 motifs.
To analyse the promoter-binding capacities of TCF4
variants also in living cells, we performed ChIPs.
Expression vectors for TCF4 isoforms were introduced
into HEK293 cells together with luciferase reporter gene
constructs containing either the Siamois promoter or the
Cdx1 promoter, respectively. As a control the promoter-
less parental plasmid pGL3-basic was used (Figure 7A).
After formaldehyde crosslinking and preparation of
fragmented chromatin, parallel immunoprecipitations
with an anti-TCF4 antibody and non-speciﬁc goat IgGs
were carried out. Plasmid DNA present in the immuno-
precipitates was quantiﬁed by real-time PCR after
normalization based on TCF4 protein content of the
immunoprecipitates as determined by western blotting
(Figure 7C). Sequences of the Cdx1 and Siamois pro-
moters were strongly enriched upon ChIP of all three
TCF4 variants (Figure 7B). In the absence of speciﬁc
Cdx1 or Siamois promoter sequences, recovery of
plasmid DNA by TCF4-ChIP was much reduced, but
not eliminated. Presumably, cryptic TCF binding sites in
Figure 7. Promoter-binding capacity of TCF4 isoforms in transfected cells. (A) Schemes of the Cdx1 and Siamois (Sia) promoter regions present in
the pGL3 basic luciferase vector. Vertical bars mark the location of TBEs. Positions of primers used for quantitative PCR are shown (demi-arrows).
Coordinates of primers and DNA fragment end points are given relative to the transcription start sites (+1; arrows) of the Cdx1 and Siamois
promoters. DNA sequences used as EMSA probes are marked by gray boxes. At the pGL3 basic backbone positions of primers refer to the parental
vector. (B) HEK293 cells were cotransfected with combinations of expression vectors for TCF4 isoforms and reporter gene constructs harbouring
Siamois or Cdx1 promoter sequences as indicated. Control samples received the empty expression vector and a promoter-less construct, respectively.
To determine promoter occupancy, cells were crosslinked 40h post transfection and solubilized fragmented chromatin was prepared. ChIP was done
with a goat polyclonal antibody against TCF4 (N-20) or non-speciﬁc goat control IgGs. Promoter DNA recovered by ChIP was quantiﬁed by
real-time PCR. Relative enrichments represent the ratio of DNA amounts obtained by speciﬁc versus non-speciﬁc precipitations. Results from at least
three independent experiments and the corresponding standard deviations are shown. (C) Abundance of TCF4 splice variants in solubilized frag-
mented chromatin from transfected HEK293 cells and their recovery by ChIP. Levels of TCF4 splice variants were monitored by western blotting
using fractions of the input chromatin and of the material immunoprecipitated by either goat control IgGs or the goat polyclonal anti-TCF4
antibody N-20. Detection was performed with the mouse monoclonal anti-TCF4 antibody 6H5-3 and appropriate peroxidase-conjugated secondary
antibodies. Results from one representative experiment are shown.
1976 Nucleic Acids Research, 2010, Vol.38, No. 6the vector backbone mediate the residual enrichment.
Importantly, however, precipitation of promoter DNA
strictly depended on expression of exogenous TCF4
demonstrating the speciﬁcity of the ChIP. Interestingly,
whereas all three TCF4 variants bound to the Siamois
promoter in a similar manner, Cdx1 sequences were
more eﬃciently precipitated by TCF4E2. Thus, superior
transactivation by TCF4E2 is reﬂected to some extent by
enhanced promoter binding in case of the Cdx1 construct
but not with the Siamois promoter. Taken together, the
results of the DNA-binding experiments in vitro and
in vivo suggest that the extended C-terminus of TCF4E
splice variants does have some inﬂuence on TCF4E2::
DNA interactions but, in addition, it appears to harbour
further functions critical for promoter activation.
DISCUSSION
The Wnt/b-catenin pathway is capable of eliciting a large
number of diﬀerent tissue-speciﬁc responses (45). The pre-
dominant Wnt eﬀect in target cells consists of changes in
gene expression at the transcriptional level and many of
the Wnt/b-catenin target genes are subject to cell-type-
speciﬁc control (45,51,52). One mechanism whereby the
Wnt/b-catenin pathway can address diﬀerent sets of
target genes, involves the use of multiple nuclear eﬀector
proteins with diﬀerent functional properties. In vertebrate
genomes, several TCF genes exist and in some cases
the complement of TCF proteins can be additionally
expanded by alternative splicing (5,6,25–27,53). To
further explore the extent of TCF structural variability
and its potential importance in transcriptional control
by Wnt/b-catenin signalling, we have undertaken a com-
prehensive characterization of splice variants derived from
the mouse Tcf7l2 gene.
Sequence diversity of Tcf7l2 splice variants
Previous studies concentrated on the analysis of alterna-
tive splicing of the human TCF7L2 gene (25–27).
Recently, a more extensive study of transcript variants
in the mouse was reported (30). We further complement
and extend this work. Overall, the mouse and human
genes turn out to be highly similar both with respect to
the regions, which exhibit sequence variability, and in view
of the combinatorial patterns of alternative exons.
However, some diﬀerences appear to exist. At present,
there is no evidence that alternative splice acceptors exist
in exons 16 and 17 of Tcf7l2 as previously reported for the
human gene (this study, 30). It is not clear whether this is a
species-speciﬁc diﬀerence or whether this reﬂects aberrant
splice events in human tumour cells. In support of the
latter possibility, it has also been described that in brain
tumours a novel exon 160 is incorporated into TCF7L2
transcripts which is not found in other cell types or
healthy tissues (26). A further diﬀerence concerns tran-
script variants which encode TCF4N. So far, these have
only been reported in mouse but not in human cells. The
strong emphasis on splice events aﬀecting exons 13–16
may have precluded their detection in the human system
up to now. Given the unique functional properties of
TCF4N (28,29,54) and its intriguing tissue distribution
might make it worthwhile to determine whether TCF4N
variants also occur in human cell types.
Even by combining the results of all currently available
studies it is not clear whether the full range of all theoret-
ically possible alternatively spliced Tcf7l2 mRNA species
is actually realized. For example, variable use of alterna-
tive splice donors and acceptors in exons 7 and 9 could
bring about four diﬀerent transcript variants. To date,
three of these four variants have been found (this study,
30). Similarly, out of 16 possible arrangements of exons
12–17, only 13 have been experimentally conﬁrmed by
sequence analyses. As a novel aspect, we show here that
exon 4 can be found in multiple TCF4E, TCF4M and
TCF4S isoforms. Although this does not exclude the pos-
sibility that some combinations among exons 4 and 13–17
are mutually exclusive, it seems that exon 4 is not specif-
ically excluded from one of the three main groups of
TCF4 isoforms.
An unexpected observation was that there are two dif-
ferent amino acid versions of the ﬁrst part of the C-clamp
derived from exon 14 or 15, respectively. Exons 14 and 15
have the same lengths and they are highly related in
sequence. Still, their translation products diﬀer at seven
out of 25 amino acid positions. The majority of these
alterations are non-conservative exchanges. Most
notably, the CRARF element is converted into a
CRALF motif. Nonetheless, our functional analyses did
not detect any striking diﬀerence between CRARF and
CRALF versions of the C-clamp with respect to their
transactivation properties. Perhaps signiﬁcantly, the
variant positions spare amino acids, which were found
to be highly conserved in evolution and which appear
crucial for C-clamp function (19,24). Thus, the CRALF
version of the C-clamp may result from an exon duplica-
tion event (25) followed by mutagenesis and selection of
neutral exchanges. This naturally occurring sequence vari-
ation could help to further distinguish functionally impor-
tant residues within the C-clamp.
In the past, diﬀerent nomenclatures were used to
denominate splice variants with diﬀerent combinations
of exons 13–16. In some cases the sorting criterion was
the presumed size of the protein products which were clas-
siﬁed as ‘L’ (long), ‘M’ (medium) and ‘S’ (short) (25–27).
Others distinguished between ‘E’ and ‘B’ forms in analogy
to transcripts derived from the TCF7 gene (5,6,18,28,32–
34). We propose a uniﬁed classiﬁcation of transcripts
according to the C-terminal amino acid composition of
their translation products. Transcripts which code for
TCF4 isoforms containing a complete C-clamp and the
two CtBP-binding motifs, represent the E-type in reminis-
cence of the structural and functional similarities to the
TCF1E variant (5,6). Transcripts which give rise to TCF4
variants with a partial C-clamp (C-clampC) form the
type ‘S’ group. Splice products coding for TCF4
isoforms lacking all of the C-clamp constitute the
M-type (hitherto ‘B’). Overall, the proposed classiﬁcation
equalizes the nomenclatures used for mouse and human
transcripts by using structurally and functionally relevant
criteria while largely maintaining the labelling previously
assigned to the human splice variants. One notable
Nucleic Acids Research,2010, Vol.38, No. 6 1977exception is the splice variant with exon combination
12–16–17 to which we now refer as TCF4M3.
Tissue-speciﬁc expression of TCF4 splice variants
Cell-type-speciﬁc expression of protein isoforms with
variable domain composition could be one way whereby
the transcriptional output of Wnt/b-catenin signalling is
diversiﬁed. While our comparative analyses show that
many Tcf7l2 transcript isoforms exhibit a broad tissue
distribution, they also reveal a few notable exceptions
with more restricted expression patterns. Transcripts con-
taining exon 4 are considerably less abundant in brain and
ES cells. Amino acids encoded by exon 4 appear to have a
dampening eﬀect on TCF4 transactivation capacity. The
underrepresentation of exon 4-containing transcripts in
brain and ES cells may indicate a need to achieve
comparably higher expression levels of TCF4-regulated
genes in these cells. A second example for TCF4 tran-
scripts with a pronounced tissue-speciﬁc expression is
provided by the variants encoding TCF4N which lack a
DNA-binding domain and a nuclear import sequence. In
functional tests, TCF4N diminishes transcriptional
activity of b-catenin/TCF-regulated promoters and redi-
rects b-catenin to other regulatory elements where it
potentiates transcriptional activity of non-TCF transcrip-
tion factors (28,29). In view of this, the reduced abun-
dance of TCF4N variants in embryonic stem cells may
indicate the requirement of an unrestrained availability
of b-catenin for TCF-controlled Wnt target genes
(55–57). A third example for transcripts with a more con-
spicuous tissue distribution are variants with exon 16
(25–27,30). Some of these (TCF4S3, TCF4S6) appear to
be particularly abundant in brain. The functional signiﬁ-
cance of this is unclear, though. Inclusion of exon 16
sequences is incompatible with the production of TCF4E
isoforms. Instead, predominantly TCF4S isoforms are
generated. Their tissue-speciﬁc representation and their
relative amounts compared to other splice forms, thus,
might be of importance in shaping a cell-type-speciﬁc
transcriptional response of the Wnt/b-catenin pathway
in the brain.
Promoter-speciﬁc transactivation by TCF4 splice variants
By comparing the transactivation potential of LEF1,
TCF1B, TCF1E and TCF3, it was found earlier that
only TCF1E was able to activate the P1 promoter of the
human LEF1 gene (19,24). Similarly, functional analyses
of LEF1 and TCF4E revealed the particular ability of
TCF4E to synergize with b-catenin and p300 in Cdx1
promoter activation (18). Here, we have extended the
functional characterization of TCF4 to additional target
gene promoters and included representatives of all three
major categories of TCF4 splice isoforms. We found that,
in principle, all splice variants tested can function as
transcriptional activators in conjunction with b-catenin.
However, promoter context strongly inﬂuences the
ability of TCF4 proteins to synergize with b-catenin as
shown by the example of the Cyclin D1 promoter which
can be bound by TCF4 but which is not stimulated by it.
Also, TCF4M1 and S2 which were ineﬀective at the Axin2
and Cdx1 promoters, possessed limited transactivation
capacity at the Siamois promoter. However, at promoter
elements where TCF4 does function as a transactivator,
TCF4E variants generally induced much higher activity
than TCF4M1 and TCF4S.
What could be the molecular basis for promoter
speciﬁcity of TCF4 transcriptional activity and the func-
tional diﬀerences between TCF4E and TCF4M/S
variants? It was suggested that TCF1E and Drosophila
dTCF are capable of dual DNA-recognition which is
mediated by both the HMG box which interacts with
the TBE core motif, and the C-clamp which contacts
50-RCCG-30 sequences or so-called helper elements
present at somewhat ﬂexible distances and orientations
relative to some core TBEs (19,24). Due to this mode of
bipartite DNA-recognition, TCF1E is thought to be able
to function at promoter elements which cannot be bound
by other TCF family members or by TCF1 isoforms
lacking a C-clamp (19). However, TCF4M1 and
TCF4S2 variants interacted with the Cdx1 promoter in
vitro and in vivo despite the absence of a C-clamp,
although they could not activate this promoter.
Moreover, TCF4E2, TCF4M1 and TCF4S2 bound in an
indistinguishable manner to the Siamois promoter whose
TBEs lack discernable 50-RCCG-30 sequences. Yet again,
transactivation by TCF4E variants vastly exceeded that by
TCF4M1 and TCF4S2. From this we conclude that dif-
ferences in promoter recognition are not responsible for
diﬀerences in promoter activation by TCF4 isoforms.
Consistent with this view, it was also previously shown
that LEF1 which does not have a C-clamp and which
does not transactivate the Cdx1 and LEF1 P1 promoters,
nonetheless binds to these DNA elements (18,19).
Interestingly, it appears from our analyses that
50-RCCG-30 sequences next to a core TBE promote
DNA binding only in case of the C-clamp-containing
TCF4E2 variant. The requirement for the 50-RCCG-30
motif was at least partially alleviated with Cdx1 and
Siamois promoter probes containing multiple core TBEs.
TCF4M1 and TCF4S2 without C-clamp and other
‘E’-type-speciﬁc amino acid sequences were seemingly
indiﬀerent towards the 50-RCCG-30 motif. One interpreta-
tion of this could be that C-terminal amino acid sequences
of TCF4E isoforms function as intramolecular inhibitors
of DNA binding. Interaction between the C-clamp and 50-
RCCG-30 sequences or intermolecular interactions with
TCF4E proteins nearby appear to alleviate this inhibition.
Obviously, this mechanism would be obsolete in case of
TCF4 variants lacking the extended C-termini of ‘E’-type
variants. From our observations it also follows that
promoter recognition and transcriptional activation in a
manner depending upon b-catenin and promoter context
are separable functions associated with the extended
‘E’-type sequences. This could occur by protein::protein
interactions between TCF4 and other transcription
factors such as p300 (18). In summary, the ability of indi-
vidual TCF proteins to interact with regulatory DNA
elements and, beyond this, to participate in promoter acti-
vation appears to depend on TCF4 protein domain com-
position, architectural diﬀerences among Wnt-inducible
promoters with respect to the arrangement of TBEs and
1978 Nucleic Acids Research, 2010, Vol.38, No. 6adjacent DNA elements, and possibly additional protein
cofactors (18,58–60).
Role of Tcf7l2 splice variants in control of proliferation
and diﬀerentiation
In mice, TCF4 deﬁciency results in perinatal lethality due
to depletion of a proliferative cell compartment in the
intestinal epithelium (61). Expression of dominant
negative dnTCF1 or dnTCF4 induces cell-cycle arrest in
human colorectal cancer cells (24,48,62). In ChIP experi-
ments, TCF4 was found to occupy cis-regulatory elements
of genes which promote cell proliferation (15,63,64). These
observations are in agreement with the view that TCF4
proteins support the oncogenic activities of the Wnt/
b-catenin signalling cascade. Recent studies, however,
ascribe tumour suppressor properties to TCF4 (65,66).
By mutational analyses the tumour inhibitory function
of TCF4 was mapped to a C-terminal domain which
encompasses the C-clamp (66). This ﬁts with the observa-
tion that a homopolymeric stretch of nine consecutive
adenosines at the 50-end of exon 17 is frequently shortened
or extended in tumour cells (26,67–69). The frame shifts
which ensue, interfere with the production of TCF4E
variants with a complete C-clamp and CtBP-binding
motifs. Seemingly, the tumour inhibitory functions of
TCF4 are speciﬁcally linked to full-length TCF4E
variants. Consistent with this idea, TCF4E isoforms are
distinguished by their unique transactivation properties at
the Axin2 and Cdx1 genes, which contribute to the sup-
pression of tumourigenesis (70–72). The assumption that
diﬀerent TCF4 isoforms are required for the control of
distinct groups of genes would allow to reconcile the
apparently conﬂicting activities of TCF4 in maintaining
cell proliferation and in suppressing tumourigenesis
(61,62,65,66). These opposing functions may simply
reﬂect promoter-speciﬁc activities of diﬀerent TCF4
splice variants. To gain further insight into this and to
precisely deﬁne the functions of TCF4 splice variants
under physiological and pathological conditions, the full
range of TCF4-regulated genes in diﬀerent cellular settings
and the dependency of their expression on the availability
of speciﬁc TCF4 isoforms will have to be analysed.
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